Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capsaicin dermal patch - Grunenthal

Next Previous
X
Search
Drug Profile

Capsaicin dermal patch - Grunenthal

Alternative Names: 8% capsaicin patch - NeurogesX; Capsaicin; NGX-4010; Qutenza; Transacin; Transdolor™ Pain Treatment System

Latest Information Update: 13 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeurogesX
  • Developer Astellas Pharma Europe Ltd; Averitas Pharma; NeurogesX
  • Class Analgesics; Antipruritics; Catechols; Local anaesthetics; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
  • Mechanism of Action GABA A receptor modulators; Melatonin receptor modulators; Substance P inhibitors; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain; Erythromelalgia; Postherpetic neuralgia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Neuropathic pain; Postherpetic neuralgia
  • Registered Diabetic neuropathies
  • No development reported Postoperative pain

Most Recent Events

  • 07 Nov 2024 Grünenthal intends to file supplemental new drug application submission for Neuropathic pain in 2026
  • 07 Nov 2024 Grünenthal completes enrolment in the phase III AV001 trial for Neuropathic pain (post-surgical neuropathic pain) (PSNP) in the Europe and USA
  • 22 Oct 2024 Grünenthal announces intention to expand label for Neuropathic pain in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top